Lafora Disease and Congenital Generalized Lipodystrophy: A Case Report

[1]  S. O’Rahilly,et al.  Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. , 2008, The Journal of clinical endocrinology and metabolism.

[2]  C. Ackerley,et al.  Typical progression of myoclonic epilepsy of the Lafora type: a case report , 2008, Nature Clinical Practice Neurology.

[3]  A. Delgado-Escueta.  Advances in Lafora progressive myoclonus epilepsy , 2007, Current neurology and neuroscience reports.

[4]  S. Ling,et al.  Lafora-Like Ground-Glass Inclusions in Hepatocytes of Pediatric Patients: A Report of Two Cases , 2007, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[5]  L. Wilkins.  Genetic diagnosis in Lafora disease: Genotype–phenotype correlations and diagnostic pitfalls , 2007, Neurology.

[6]  K. Yamakawa,et al.  Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. , 2007, Human molecular genetics.

[7]  A. K. Agarwal,et al.  Genetic basis of lipodystrophies and management of metabolic complications. , 2006, Annual review of medicine.

[8]  S. Scherer,et al.  Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. , 2005, Human molecular genetics.

[9]  C. Worby,et al.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Scherer,et al.  Progressive myoclonus epilepsy with polyglucosans (Lafora disease) , 2004, Neurology.

[11]  J. Serratosa,et al.  Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. , 2003, Human molecular genetics.

[12]  S. O’Rahilly,et al.  Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy , 2002, Journal of medical genetics.

[13]  J. Papp,et al.  Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13 , 2001, Nature Genetics.

[14]  B. Minassian.  Lafora's disease: towards a clinical, pathologic, and molecular synthesis. , 2001, Pediatric neurology.

[15]  K. Yamakawa,et al.  Advances in the genetics of progressive myoclonus epilepsy. , 2001, American journal of medical genetics.

[16]  S. Scherer,et al.  Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy , 2000, Neurology.

[17]  S. Scherer,et al.  Identification of new and common mutations in the EPM2A gene in Lafora disease , 2000, Neurology.

[18]  A. Bowcock,et al.  A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. , 1999, The Journal of clinical endocrinology and metabolism.

[19]  D. Rénier,et al.  Axilla skin biopsy: A reliable test for the diagnosis of Lafora's disease , 1987, Annals of neurology.

[20]  S. Carpenter,et al.  Sweat gland duct cells in Lafora disease , 1981, Neurology.

[21]  M. Seip.  Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? , 1959, Acta paediatrica.

[22]  M. Seip.  38. Congenital Hyperpituitarism of Hypothalamic Origin; A new Diencephalic Syndrome with Endocrine Manifestations , 1959, Acta paediatrica. Supplementum.

[23]  W. Berardinelli.  An undiagnosed endocrinometabolic syndrome: report of 2 cases. , 1954, The Journal of clinical endocrinology and metabolism.

[24]  S. Scherer,et al.  On the road to tractability: the current biochemical understanding of progressive myoclonus epilepsies. , 2006, Advances in neurology.

[25]  A. Beydoun,et al.  Biopsy results in a kindred with Lafora disease. , 1993, Archives of neurology.